PALOMA-2 was a phase III study of palbociclib and letrozole as first-line therapy for postmenopausal women with estrogen-receptor (ER)-positive, HER2-negative advanced breast cancer [15]. This evidence concerns the gene ERBB2 and breast carcinoma.